Neoadjuvant Anbenitamab and HB1801 in ERBB2-Positive Breast Cancer: A Phase 3 Randomized Clinical Trial.
Li J, Liu T, Yu KD, Yang H, Huang Z, Zeng Y, Ji P, Hou X, Liu C, Zhang Y, Li N, Ouyang Z, Wu X, Bai X, Guo Y, Han G, Cui S, Zhu Z, Zhang Y, Hu X, Ma X, Fu P, Zhu J, Dong Y, Wu T, Jia H, Xu F, Ren Y, Nie J, Bing D, Mu Q, Sun T, Luo J, Song Z, Kong X, Zhang H, Wu Z, Wang Z, Song D, Jia H, Tao W, Fan P, Yao F, Ru C, Lai G, Zhou X, Li T, Deng C, Jiang X, Wang X, Wang J, Xiong D, Zhang S, Yang H, Yao Y, Yin G, Yao G, Zhou L, Wang S, Yu Z, Yu Y, Lv Y, Qian H, Li H, Guo W, Huang W, Xiang S, Zou K, He H, Fan L, Shao ZM; BCTOP study group.
Li J, et al. Among authors: fan l.
JAMA Oncol. 2026 Sep 3:e263329. doi: 10.1001/jamaoncol.2026.3329. Online ahead of print.
JAMA Oncol. 2026.
PMID: 42690668
Free PMC article.